Tamsulosin Hydrochloride Capsule
Product Images NDC 68071-4443

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 68071-4443). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 4443 9

Label for Tamsulosin Hydrochloride 0.4 mg capsules from NuCare Pharmaceuticals, Inc. The label indicates 90 capsules in the package. Capsules are described as oblong olive green opaque/orange opaque with imprint 'D' on the cap and '53' on the body. Includes product number P1849090 and storage temperature instructions.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

This line graph shows mean plasma concentrations of Tamsulosin Hydrochloride over 36 hours following a single 0.4 mg dose administered as capsules. It compares concentrations under fasted and fed conditions in eight subjects, with plasma concentration (ng/mL) on the y-axis and time in hours on the x-axis.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph showing the mean change from baseline in total AUA symptom score over 13 weeks of treatment in Study 1. The x-axis represents the duration of treatment in weeks (0, 1, 2, 4, 7, 10, 13, LOCF), and the y-axis shows the mean change in score from 0 to -11. Three treatments are compared: 0.8 mg dose, 0.4 mg dose, and placebo. Both doses show greater reduction in symptom score over time compared to placebo, with 0.8 mg showing the largest decrease.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph illustrating mean change from baseline in Total AUA Symptom Score over 13 weeks in Study 2. The x-axis shows Duration of Treatment (weeks) and the y-axis shows Mean Change. Three treatment groups are plotted: 0.8 mg (circles), 0.4 mg (triangles), and placebo (squares). The placebo group shows the least symptom improvement, while both Tamsulosin doses show greater decreases in symptom scores over time.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' displaying mean change in mL/sec over a duration of treatment in weeks for three groups: 0.8 mg dose, 0.4 mg dose, and placebo. The x-axis shows treatment duration from baseline to 13 weeks and last observation carried forward (LOCF), and the y-axis shows mean change ranging from 0 to 3 mL/sec. The graph compares urine flow rate changes across different treatment groups.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing mean change in urine flow rate over treatment duration in weeks. Three treatment groups are plotted: 0.8 mg, 0.4 mg, and placebo. The y-axis represents mean change in mL/sec, and the x-axis represents treatment duration from 0 to 13 weeks plus last observation carried forward (LOCF). Each treatment group shows different trends in mean urine flow rate increase throughout the study period.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride, showing the molecular formula with functional groups including an aromatic ring, methoxy, amino, ether, and hydrochloride components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.